Class patent landscape
Kinase Inhibitor
Cross-drug patent estate across 42 approved drugs in the kinase inhibitor class. Loss-of-exclusivity timeline, sponsor concentration, and per-drug links to full patent landscapes.
Approved drugs
42
with patent data
OB patents
400
across the class
Patent families
148
8,173 docs · 71 countries
Earliest US LOE
Jun 30, 2028
first drug off patent
Latest US LOE
Apr 29, 2045
last drug off patent
Loss-of-exclusivity waterfall
Drugs in the kinase inhibitor class sorted by US Orange Book expiry — earliest LOE first. Each row links to the drug's full patent landscape.
| Drug | Sponsor | OB patents | Families | Intl docs | Latest US expiry | |
|---|---|---|---|---|---|---|
| AFINITOR everolimus | Novartis | 3 | 2 | 290 | Jun 30, 2028 +2y | View → |
| CAPRELSA vandetanib | Sanofi | 1 | 1 | 49 | Aug 7, 2028 +2y | View → |
| NEXAVAR sorafenib tosylate | Bayer | 2 | 2 | 106 | Sep 9, 2028 +2y | View → |
| JAKAFI ruxolitinib phosphate | INCYTE CORP | 16 | 2 | 338 | Dec 11, 2028 +2y | View → |
| KOSELUGO selumetinib sulfate | AstraZeneca | 8 | 3 | 263 | Mar 25, 2029 +3y | View → |
| XALKORI crizotinib | PF PRISM CV | 3 | 3 | 143 | Nov 5, 2029 +3y | View → |
| VONJO pacritinib citrate | SOBI | 3 | 2 | 106 | Mar 24, 2030 +4y | View → |
| RYDAPT midostaurin | Novartis | 2 | 2 | 96 | Dec 1, 2030 +4y | View → |
| GILOTRIF afatinib dimaleate | Boehringer Ingelheim | 10 | 5 | 189 | Jan 4, 2031 +5y | View → |
| VERZENIO abemaciclib | Eli Lilly | 1 | 1 | 55 | Sep 27, 2031 +5y | View → |
| ZELBORAF vemurafenib | HOFFMANN LA ROCHE | 6 | 4 | 241 | Jun 5, 2032 +6y | View → |
| ZYDELIG idelalisib | Gilead Sciences | 4 | 2 | 50 | Sep 1, 2033 +7y | View → |
| OJEMDA tovorafenib | DAY ONE BIOPHARMS | 2 | 2 | 76 | Jun 22, 2035 +9y | View → |
| ALUNBRIG brigatinib | Takeda | 4 | 4 | 140 | Nov 9, 2035 +9y | View → |
| CALQUENCE acalabrutinib maleate | AstraZeneca | 9 | 4 | 250 | Jun 30, 2036 +10y | View → |
| AUGTYRO repotrectinib | Bristol-Myers Squibb | 5 | 3 | 212 | Jul 23, 2036 +10y | View → |
| IBRANCE palbociclib | Pfizer | 6 | 3 | 211 | Feb 18, 2037 +11y | View → |
| VITRAKVI larotrectinib sulfate | Bayer | 20 | 6 | 310 | May 15, 2037 +11y | View → |
| INLYTA axitinib | PF PRISM CV | 6 | 3 | 133 | Jul 11, 2037 +11y | View → |
| ZYKADIA ceritinib | Novartis | 8 | 6 | 323 | Dec 12, 2037 +11y | View → |
| BALVERSA erdafitinib | Johnson & Johnson | 8 | 6 | 379 | Feb 1, 2038 +12y | View → |
| TUKYSA tucatinib | SEAGEN | 7 | 4 | 255 | Apr 26, 2038 +12y | View → |
| ITOVEBI inavolisib | Roche | 7 | 3 | 213 | Jun 13, 2038 +12y | View → |
| LORBRENA lorlatinib | Pfizer | 4 | 3 | 155 | Oct 3, 2038 +12y | View → |
| LENVIMA lenvatinib mesylate | EISAI INC | 20 | 8 | 350 | Nov 14, 2038 +12y | View → |
| GAVRETO pralsetinib | BLUEPRINT MEDICINES | 4 | 2 | 108 | Apr 2, 2039 +13y | View → |
| RETEVMO selpercatinib | Eli Lilly | 12 | 3 | 142 | Apr 9, 2039 +13y | View → |
| IMBRUVICA ibrutinib | PHARMACYCLICS LLC | 83 | 7 | 735 | Jun 13, 2039 +13y | View → |
| DANZITEN nilotinib tartrate | AZURITY | 3 | 1 | 17 | Feb 17, 2040 +14y | View → |
| PEMAZYRE pemigatinib | INCYTE CORP | 4 | 3 | 217 | Aug 29, 2040 +14y | View → |
| FYARRO sirolimus | AADI SUB | 7 | 5 | 218 | Oct 27, 2040 +14y | View → |
| WAYRILZ rilzabrutinib | Sanofi | 6 | 4 | 130 | Feb 19, 2041 +15y | View → |
| HERNEXEOS zongertinib | Boehringer Ingelheim | 2 | 2 | 143 | Jul 20, 2041 +15y | View → |
| LAZCLUZE lazertinib mesylate | Johnson & Johnson | 7 | 6 | 238 | Jul 31, 2041 +15y | View → |
| JAYPIRCA pirtobrutinib | LOXO ONCOL | 7 | 2 | 151 | Sep 13, 2041 +15y | View → |
| AYVAKIT avapritinib | BLUEPRINT MEDICINES | 8 | 2 | 105 | Mar 7, 2042 +16y | View → |
| QINLOCK ripretinib | DECIPHERA PHARMS | 41 | 7 | 204 | Oct 5, 2042 +16y | View → |
| TAGRISSO osimertinib mesylate | AstraZeneca | 5 | 3 | 247 | Nov 25, 2042 +16y | View → |
| BRUKINSA zanubrutinib | BEONE MEDICINES USA | 13 | 5 | 178 | Jan 18, 2043 +17y | View → |
| RHAPSIDO remibrutinib | Novartis | 3 | 2 | 139 | Jan 19, 2043 +17y | View → |
| GOMEKLI mirdametinib | SPRINGWORKS | 22 | 6 | 119 | Oct 9, 2044 +18y | View → |
| ROMVIMZA vimseltinib | DECIPHERA PHARMS | 8 | 5 | 149 | Apr 29, 2045 +19y | View → |
Sponsor concentration
Which companies anchor the IP across this class.
Pro Sponsor concentration — Which sponsors anchor the IP across the class
See what Pro includes ↓ Methodology & data sources
- Drugs in class: aggregated from
drug.pharmClassEpcfield. Drugs without EPC tags are not included here (data gap, not coverage limitation). - Patent data: per-drug patent thickets from FDA Orange Book / Purple Book + BigQuery family expansion. See individual drug patent pages for source detail.
- LOE waterfall: sorted by
latestPatentExpiryfrom Orange Book. Reflects US patent term adjustments (PTA) but not exclusivity overlays (ODE, NPP, PED). - Class-level analysis: sums across per-drug thickets. Same patent family may appear in multiple drugs (e.g., Jakafi + Opzelura share composition family) — counted once per family per drug for OB totals.
Intelligence, not legal advice. Class-level summary reflects what's listed publicly. Generic launch dynamics depend on per-drug NCE/ODE/PED overlays, ANDA Para IV outcomes, and BPCIA settlements not captured here.
TheraRadar Pro — patent intelligence
Free covers what's publicly listed: Orange Book patents, basic stats, composition expiry. Pro adds the deeper view: LLM-driven estate analysis, full international family thicket, and (coming soon) alerts + exports.
Always free
- • Orange Book patent table (every patent, family, use code, expiry)
- • Stat strip — OB count, families, global doc footprint, multiplier
- • Composition family priority + nominal global expiry
- • International vs US expiry comparison
- • Coverage status + methodology
- • LOE waterfall across all approved drugs in the class
PRO
What Pro adds today
- Estate analysis (sections 2-5) — Composition anchor, lifecycle layers, international vs US, strategic outlook
- Full patent families table — Country lists, doc counts, priority dates per family
- Sponsor concentration — Who owns the IP across the class
- International nominal expiries — Priority + 20 years per family with global vs US gap
$99/year. Cancel anytime. Single sign-on via Google.
Class patent data updated: Jun 17, 2026